Search clinical trials for: Combination 3BNC117-LS-J and 10-1074-LS-J

Total 34 results

International AIDS Vaccine Initiative
Brigham and Women's Hospital; Fred Hutchinson Cancer Center; Rockefeller University

Active, not recruiting

Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults

HIV-1-infection

United States, Uganda, Kenya, Rwanda, South Africa
Advancing Clinical Therapeutics Globally for HIV...
National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting

Pausing Antiretroviral Treatment Under Structured Evaluation (PAUSE)

HIV-1-infection

Malawi, Botswana, South Africa
Advancing Clinical Therapeutics Globally for HIV...
National Institute of Allergy and Infectious Diseases (NIAID)

Not yet recruiting

Antiretrovirals Combined With Antibodies for HIV-1 Cure In Africa (ACACIA)

HIV-1-infection
National Institute of Allergy and Infectious Diseases...
Rockefeller University

Withdrawn

Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy

HIV-1

United States
Imperial College London
Bill and Melinda Gates Foundation; University of Oxford; Rockefeller University

Recruiting

A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs). (RIO)

HIV/AIDS and Infections

Denmark, United Kingdom
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir (GS-6207) in Virologically Suppressed Adults With HIV-1 Infection

HIV-1 Infection

United States
Rockefeller University

Completed

First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS

Human Immunodeficiency Virus

United States
National Institute of Allergy and Infectious Diseases...
Gilead Sciences; University of Oxford

Recruiting

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

HIV-1-infection

United States, Brazil
Rockefeller University
National Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaborators

Completed

3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals

Human Immunodeficiency Virus

United States
ANRS, Emerging Infectious Diseases
Institut Pasteur; Rockefeller University

Recruiting

Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control (RHIVIERA-02)

HIV/AIDS and Infections

France
Rockefeller University

Completed

3BNC117-LS First-in-Human Phase 1 Study

Human Immunodeficiency Virus

United States
Rockefeller University
National Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaborators

Recruiting

3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)

Human Immunodeficiency Virus

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Combination Therapy With 3BNC117 and 10-1074 in HIV-Infected Individuals

HIV

United States
Rockefeller University

Completed

3BNC117 and 10-1074 in HIV Uninfected Adults

Human Immunodeficiency Virus

United States
University of Aarhus
Odense University Hospital; Oslo University Hospital; Rigshospitalet, Denmark; Hvidovre... and other collaborators

Completed

Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV (TITAN)

HIV-1-infection

Norway, Denmark, United States, Australia
Light Sciences Oncology
Mundipharma Research Limited

Completed

A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia

United States
Rockefeller University
National Institute of Allergy and Infectious Diseases (NIAID); Montefiore Medical... and other collaborators

Completed

3BNC117 and 10-1074 in ART-treated Individuals

Human Immunodeficiency Virus

United States
Rockefeller University
University Hospital of Cologne

Completed

3BNC117 and 10-1074 in HIV-infected Individuals

Human Immunodeficiency Virus (HIV)

United States, Germany
Luis Montaner
National Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaborators

Unknown

Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2) (BEAT-2)

HIV/AIDS | HIV | HIV-1 Infection

United States
Retinal Consultants of Arizona
Allergan

Completed

A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus

Diabetes Mellitus | Macular Edema

United States
AbbVie (prior sponsor, Abbott)
Quintiles, Inc.

Completed

Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects

Parkinson's Disease | Dyskinesias | Severe Motor Fluctuations

United States, Germany, New Zealand
Orion Corporation, Orion Pharma

Completed

Comparison of Tiotropium Absorption From Tiotropium Easyhaler and Spiriva HandiHaler (TEMPO)

Healthy Volunteers

Finland
AbbVie

Completed

A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications

Advanced Parkinson's Disease
AbbVie (prior sponsor, Abbott)
Quintiles, Inc.

Completed

Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease

Advanced Parkinson's Disease

United States, Australia, Canada, Czech Republic, Finland, Germany, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Russian Federation, Spain, Thailand, United Kingdom
AbbVie

Completed

A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)

Advanced Parkinson's Disease

United States, Australia, Canada, Germany, Greece, Italy, Korea, Republic of, Spain, Sweden
National Institute of Allergy and Infectious Diseases...
Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; AIDS Clinical Trials... and other collaborators

Completed

ACTIV-2: A Study for Outpatients With COVID-19

Covid19 | Coronavirus

United States, Argentina, Brazil, Guatemala, Mexico, Philippines, Puerto Rico, South Africa, Canada
RedHill Biopharma Limited

Completed

Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease (MAPUS2)

Crohn Disease

United States, Canada, Czechia, Israel, New Zealand, Poland, Serbia
University of Colorado, Denver
Colorado Clinical & Translational Sciences Institute

Terminated

Jet Injection of 1% Buffered Lidocaine Versus Topical EMLA for Local Anesthesia Before Lumbar Puncture in Children (JTIP)

Lumbar Puncture | Topical Analgesia

United States
AbbVie (prior sponsor, Abbott)

Completed

A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease

Advanced Parkinson's Disease
AbbVie
IQVIA, formerly Quintiles

Completed

Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease

Advanced Parkinson's Disease

United Kingdom, Czechia, United States, Australia, Canada, Israel, New Zealand, Poland, Portugal, Russian Federation, Thailand
AbbVie (prior sponsor, Abbott)
Quintiles, Inc.

Completed

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

Advanced Parkinson's Disease

United States, Germany
AbbVie (prior sponsor, Abbott)
Quintiles, Inc.

Completed

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

Advanced Parkinson's Disease

United States, New Zealand
AbbVie (prior sponsor, Abbott)

Completed

Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact (DAPHNE)

Advanced Idiopathic Parkinson's Disease

Search clinical trials for: Combination 3BNC117-LS-J and 10-1074-LS-J

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations